{"nctId":"NCT01012674","briefTitle":"Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)","startDateStruct":{"date":"2009-10"},"conditions":["Cerebral Arterial Diseases"],"count":211,"armGroups":[{"label":"Dotarem and TOF MRA","type":"EXPERIMENTAL","interventionNames":["Drug: Dotarem","Other: TOF MRA"]}],"interventions":[{"name":"Dotarem","otherNames":["Gadoterate meglumine"]},{"name":"TOF MRA","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female, aged more than 18 years\n* Strongly suspected of having carotid or vertebral arterial disease\n* Scheduled (or to be scheduled) to undergo computed tomography angiography (CTA) examination\n\nExclusion Criteria:\n\n* Known grade IV or V chronic kidney disease (GFR\\<30 mL/min/1.73m²)\n* Contraindication to MRI\n* Acute renal dysfunction within the 6 months preceding Dotarem®-enhanced MRA examination","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Technical Failure Rate","description":"Rate of non-assessable arterial segments as measured by 3 independent readers in off-site evaluation of TOF-MRA and Dotarem-enhanced MRA (re-read DGD-44-061).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.55","spread":null},{"groupId":"OG001","value":"29.22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.57","spread":null},{"groupId":"OG001","value":"17.65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.68","spread":null},{"groupId":"OG001","value":"23.07","spread":null}]}]}]},{"type":"PRIMARY","title":"Sensitivity","description":"Rate of true stenotic segments (i.e. with stenosis \\>= 70%) of TOF and Dotarem-enhanced MRA evaluated by 3 independent off-site readers at the segment level, with CTA as standard of truth (re-read DGD-44-061).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.65","spread":null},{"groupId":"OG001","value":"65.22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.57","spread":null},{"groupId":"OG001","value":"73.91","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.00","spread":null},{"groupId":"OG001","value":"66.30","spread":null}]}]}]},{"type":"PRIMARY","title":"Specificity","description":"Rate of true non-stenotic segments (i.e. without stenosis \\>= 70%) of TOF and Dotarem-enhanced MRA evaluated by 3 independent off-site readers at the segment level, with CTA as standard of truth (re-read DGD-44-061).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.03","spread":null},{"groupId":"OG001","value":"84.34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.40","spread":null},{"groupId":"OG001","value":"89.51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.61","spread":null},{"groupId":"OG001","value":"88.40","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":187},"commonTop":["Headache","Rash","Anxiety"]}}}